FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring

Jolijn W Groeneweg*, Joline F Roze, Edith D J Peters, Ferdinando Sereno, Anna G J Brink, Sterre T Paijens, Hans W Nijman, Hannah S van Meurs, Luc R C W van Lonkhuijzen, Jurgen M J Piek, Christianne A R Lok, Glen R Monroe, Gijs W van Haaften, Ronald P Zweemer

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

1 Downloads (Pure)

Samenvatting

OBJECTIVE: Adult granulosa cell tumors (aGCTs) represent a rare, hormonally active subtype of ovarian cancer that has a tendency to relapse late and repeatedly. Current serum hormone markers are inaccurate in reflecting tumor burden in a subset of aGCT patients, indicating the need for a novel biomarker. We investigated the presence of circulating tumor DNA (ctDNA) harboring a FOXL2 or TERT promoter mutation in serial plasma samples of aGCT patients to determine its clinical value for monitoring disease.

METHODS: In a national multicenter study, plasma samples (n = 110) were prospectively collected from 21 patients with primary (n = 3) or recurrent (n = 18) aGCT harboring a FOXL2 402C > G and/or TERT (C228T or C250T) promoter mutation. Circulating cell-free DNA was extracted and assessed for ctDNA containing one of either mutations using droplet digital PCR (ddPCR). Fractional abundance of FOXL2 mutant and TERT mutant ctDNA was correlated with clinical parameters.

RESULTS: FOXL2 mutant ctDNA was found in plasma of 11 out of 14 patients (78.6%) with aGCT with a confirmed FOXL2 mutation. TERT C228T or TERT C250T mutant ctDNA was detected in plasma of 4 of 10 (40%) and 1 of 2 patients, respectively. Both FOXL2 mutant ctDNA and TERT promoter mutant ctDNA levels correlated with disease progression and treatment response in the majority of patients.

CONCLUSIONS: FOXL2 mutant ctDNA was present in the majority of aGCT patients and TERT promoter mutant ctDNA has been identified in a smaller subset of patients. Both FOXL2 and TERT mutant ctDNA detection may have clinical value in disease monitoring.

Originele taal-2English
Pagina's (van-tot)413-420
Aantal pagina's8
TijdschriftGynecologic Oncology
Volume162
Nummer van het tijdschrift2
Vroegere onlinedatum1-jun-2021
DOI's
StatusPublished - aug-2021

Citeer dit